Literature DB >> 3893693

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

J Robert, P Vrignaud, T Nguyen-Ngoc, A Iliadis, L Mauriac, P Hurteloup.   

Abstract

We have studied the metabolism and pharmacokinetics of epirubicin (4'-epidoxorubicin), as compared to those of doxorubicin, in a total of 16 patients with metastatic breast cancer. Epirubicin metabolism markedly differs from that of doxorubicin, in that large amounts of glucuronides of epirubicinol and epirubicin were observed in plasma as well as in urine samples. The total plasma clearance of epirubicin was significantly higher than that of doxorubicin; this was interpreted as due to an increase of the distribution volume of epirubicin, since the terminal plasma half-lives of both drugs were similar. No significant modifications were observed in patients with hepatic metastases. The differences in the pharmacokinetic and metabolic properties of the two drugs may be responsible for the differences in toxicity that have been noticed between them in previous phase I and II studies.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3893693

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  38 in total

1.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

Authors:  P Jakobsen; L Bastholt; M Dalmark; P Pfeiffer; D Petersen; S B Gjedde; E Sandberg; C Rose; O S Nielsen; H T Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 6.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; B Melotti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

10.  Disposition of epirubicin and metabolites with repeated courses to cancer patients.

Authors:  R G Morris; D Kotasek; G Paltridge
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.